Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastrointestinal Endoscopy
Conditions
Gastrointestinal Endoscopy, Gastrointestinal Polypectomy
Trial Timeline
Aug 1, 2010 → Nov 1, 2010
NCT ID
NCT01189604About Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) is a phase 2 stage product being developed by Johnson & Johnson for Gastrointestinal Endoscopy. The current trial status is completed. This product is registered under clinical trial identifier NCT01189604. Target conditions include Gastrointestinal Endoscopy, Gastrointestinal Polypectomy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01189604 | Phase 2 | Completed |
Competing Products
20 competing products in Gastrointestinal Endoscopy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Raludotatug Deruxtecan (R-DXd) | Daiichi Sankyo | Phase 2 | 52 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 1/2 | 41 |
| DS-6157a | Daiichi Sankyo | Phase 1 | 33 |
| DS-8201a + Physician's Choice | Daiichi Sankyo | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 2 | 52 |
| Gemcitabine | Eli Lilly | Phase 1/2 | 41 |
| Olaratumab | Eli Lilly | Phase 2 | 52 |
| pemetrexed + cisplatin | Eli Lilly | Phase 2 | 52 |
| cetuximab | Eli Lilly | Phase 2 | 52 |
| BBI503 | Sumitomo Pharma | Phase 2 | 52 |
| BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + Regorafenib | Sumitomo Pharma | Phase 1/2 | 41 |
| Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS) | Johnson & Johnson | Phase 3 | 77 |
| Remimazolam Tosilate | Jiangsu Hengrui Medicine | Approved | 85 |
| Famitinib capsules + Sunitinib Capsules | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Esomeprazole IV + Omeprazole IV | AstraZeneca | Phase 3 | 77 |
| Durvalumab + FLOT chemotherapy | AstraZeneca | Phase 3 | 77 |
| Esomeprazole | AstraZeneca | Phase 3 | 77 |
| AZD2171 | AstraZeneca | Phase 2 | 52 |
| Esomeprazole | AstraZeneca | Phase 3 | 77 |